Gain Therapeutics
GANX
GANX
24 hedge funds and large institutions have $4.95M invested in Gain Therapeutics in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding
Funds holding: →
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
13% less capital invested
Capital invested by funds: $5.68M → $4.95M (-$725K)
Holders
24
Holding in Top 10
–
Calls
$54K
Puts
$20K
Top Buyers
| 1 | +$623K | |
| 2 | +$137K | |
| 3 | +$41.2K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$31.1K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$28K |
Top Sellers
| 1 | -$56.3K | |
| 2 | -$14.7K | |
| 3 | -$13.4K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.84K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3.75K |